Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ImmunityBio (IBRX) Gross Margin: 2014-2025

Historic Gross Margin for ImmunityBio (IBRX) over the last 12 years, with Sep 2025 value amounting to 99.45%.

  • ImmunityBio's Gross Margin fell 55.00% to 99.45% in Q3 2025 from the same period last year, while for Sep 2025 it was 99.55%, marking a year-over-year decrease of 45.00%. This contributed to the annual value of 100.00% for FY2024, which is negligibly% changed negligibly from last year.
  • Per ImmunityBio's latest filing, its Gross Margin stood at 99.45% for Q3 2025, which was down 0.04% from 99.49% recorded in Q2 2025.
  • Over the past 5 years, ImmunityBio's Gross Margin peaked at 100.00% during Q1 2021, and registered a low of 99.45% during Q3 2025.
  • Over the past 3 years, ImmunityBio's median Gross Margin value was 100.00% (recorded in 2024), while the average stood at 99.87%.
  • Data for ImmunityBio's Gross Margin shows a maximum YoY tumbled of 55bps (in 2025) over the last 5 years.
  • Over the past 5 years, ImmunityBio's Gross Margin (Quarterly) stood at 100.00% in 2021, then remained steady at 100.00% in 2022, then remained steady at 100.00% in 2023, then remained steady at 100.00% in 2024, then plummeted by 55bps to 99.45% in 2025.
  • Its Gross Margin was 99.45% in Q3 2025, compared to 99.49% in Q2 2025 and 99.65% in Q1 2025.